Hodgkin Lymphoma

While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. However, the current evidence is largely derived from retrospective and non-randomized studies. Prospective, comparative trials are warranted to validate these findings and to better define the optimal LD strategy across disease types and CAR-T platforms.

P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS

TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.

P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended

P2, N=1, Completed, Centre Hospitalier Universitaire, Amiens | Recruiting --> Completed | N=114 --> 1

P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine

Suppressive myeloid niches were preferentially enriched around LMP1-expressing tumour cells, a feature not observed in the other EBV-associated conditions. Together, these findings indicate that EBV⁺DLBCL is driven by the convergence of systemic antiviral immune dysfunction and an LMP1-dependent suppressive tumour microenvironment.

P1, N=42, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting

The patient achieved complete clinical, biochemical and radiological remission following systemic corticosteroid therapy. This case highlights the importance of a rigorous differential diagnostic approach and careful clinicoradiological-histopathological correlation in rare presentations of sarcoidosis.

Although morphology and immunohistochemistry are usually sufficient to separate CHL from NLPHL, determining light chain restriction by K/L dual ISH could provide a valuable adjunct in challenging cases, potentially improving diagnostic accuracy and patient outcomes.

This review explores the function of newly recognized kinases in lymphoma pathogenesis, such as CK1, CK2 and others, highlighting their interaction with epigenetic regulation. The therapeutic potential of targeting simultaneously signaling and epigenetic pathways is proposed as a potential innovative strategy in the treatment of lymphomas.